Company research
Pulmatrix, Inc.
CIK 1574235Updated Sep 24, 2026
SecurityPULM · NASDAQ · equity
Name history
Ruthigen, Inc. · through Jun 16, 2015
PULM price & chart
Loading TradingView…
NASDAQ:PULM on TradingView ↗In the news
Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets News provided by Pulmatrix Inc. Oct 16, 2025, 08:05 ET Share this article Share to X Share this article Share to X As part of the proposed merger, Pulmatrix currently intends to divest its ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 4,139,000Source | 9,943,000Source | 33,958,000Source | 40,953,000Source |
| Property, Plant and Equipment, NetUSD | — | — | 1,158,000Source | 235,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 4,088,000Source | 9,521,000Source | 19,173,000Source | 35,628,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | — | 928,000Source | 1,298,000Source |
| Assets, CurrentUSD | 4,129,000Source | 9,920,000Source | 20,843,000Source | 38,147,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 41,000Source | 399,000Source | 742,000Source | 1,068,000Source |
| Operating Lease, Right-of-Use AssetUSD | — | — | 10,309,000Source | 710,000Source |
| Other Assets, NoncurrentUSD | — | 13,000Source | 176,000Source | 389,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 329,000Source | 996,000Source | 15,963,000Source | 9,844,000Source |
| Stockholders’ equity: | ||||
| Additional Paid in CapitalUSD | 306,128,000Source | 306,103,000Source | 305,592,000Source | 304,585,000Source |
| Retained Earnings (Accumulated Deficit)USD | -302,318,000Source | -297,156,000Source | -287,597,000Source | -273,476,000Source |
| Stockholders' Equity Attributable to ParentUSD | 3,810,000Source | 8,947,000Source | 17,995,000Source | 31,109,000Source |
| Liabilities and EquityUSD | 4,139,000Source | 9,943,000Source | 33,958,000Source | 40,953,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 329,000Source | 929,000Source | 3,909,000Source | 5,022,000Source |
| Operating Lease, Liability, CurrentUSD | — | — | 429,000Source | 857,000Source |
| Accounts Payable, CurrentUSD | 272,000Source | 809,000Source | 1,915,000Source | 1,188,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | — | 8,327,000Source | — |
| Additional Financial Items | ||||
| Deferred Revenue, CurrentUSD | — | — | 618,000Source | 1,339,000Source |
| Deferred Revenue, NoncurrentUSD | — | — | 3,727,000Source | 4,822,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | — | 106,000Source | 134,000Source | 162,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 25,000Source | 511,000Source | 954,000Source | 1,114,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | — | -928,000Source | -370,000Source | 1,231,000Source |
| Increase (Decrease) in Accounts PayableUSD | -537,000Source | -1,106,000Source | 727,000Source | 511,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -5,433,000Source | -10,716,000Source | -15,985,000Source | -19,356,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | -398,000Source | -676,000Source | -86,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | 398,000Source | 676,000Source | 86,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | 53,000Source | 1,230,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -5,433,000Source | -11,114,000Source | -16,608,000Source | -18,212,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 25,000Source | 511,000Source | 954,000Source | 1,114,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | -2,618,000Source | -8,000Source | — |
| Gain (Loss) on Termination of LeaseUSD | — | -2,618,000Source | — | — |
| General and Administrative ExpenseUSD | 5,131,000Source | 7,785,000Source | 6,520,000Source | 6,778,000Source |
| Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| Investment Income, InterestUSD | 144,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -5,162,000Source | -9,559,000Source | -14,121,000Source | -18,836,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -18,836,000Source |
| Nonoperating Income (Expense)USD | 7,000Source | 204,000Source | 619,000Source | 111,000Source |
| Operating ExpensesUSD | 5,169,000Source | 17,569,000Source | 22,038,000Source | 25,018,000Source |
| Other Nonoperating Income (Expense)USD | -204,000Source | -196,000Source | -248,000Source | -198,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | 53,000Source | 1,382,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | — | 7,806,000Source | 7,298,000Source | 6,071,000Source |
| Operating Income (Loss)USD | -5,169,000Source | -9,763,000Source | -14,740,000Source | -18,947,000Source |
| Other Nonoperating Income (Expense)USD | -204,000Source | -196,000Source | -248,000Source | -198,000Source |
| Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -5,162,000Source | -9,559,000Source | -14,121,000Source | -18,836,000Source |
| Earnings Per Share, BasicUSD per share | -1.41Source | -2.62Source | -3.87Source | -5.46Source |
| Earnings Per Share, DilutedUSD per share | -1.41Source | -2.62Source | -3.87Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 3,652,285Source | 3,652,285Source | 3,651,911,000Source | 3,447,701Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 3,652,285Source | 3,652,285Source | 3,651,911,000Source | — |
| Additional Financial Items | ||||
| Depreciation, Depletion and Amortization, NonproductionUSD | — | 106,000Source | 134,000Source | 162,000Source |
| General and Administrative ExpenseUSD | 5,131,000Source | 7,785,000Source | 6,520,000Source | 6,778,000Source |
| Interest Income (Expense), NetUSD | — | 467,000Source | 867,000Source | 309,000Source |
| Investment Income, InterestUSD | 144,000Source | — | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -18,836,000Source |
| Nonoperating Income (Expense)USD | 7,000Source | 204,000Source | 619,000Source | 111,000Source |
| Operating ExpensesUSD | 5,169,000Source | 17,569,000Source | 22,038,000Source | 25,018,000Source |
| Research and Development ExpenseUSD | 38,000Source | 7,166,000Source | 15,518,000Source | 18,240,000Source |
Offerings
Registration 333-297342
Registration 333-284993
Filing attachments
ex99-1.htm · 8-K · 2026-08-13
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger Form S-4 filed related to the announced merger agreement with Eos SENOLYTIX Framingham, Mass., August 13, 2026 - Pulmatrix, Inc. (“Pulmatrix” or the “Company”) (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical…
Read attachment ↗ex107.htm · S-4 · 2026-07-09
Calculation of Filing Fee Tables S-4 Pulmatrix, Inc. ──────────────────────────────────── Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable ─────────────────────────────────────────────────────────────────────────────── Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Pric…
Read attachment ↗ex99-1.htm · S-4 · 2026-07-09
EX-99.1 13 ex99-1.htm EX-99.1 Exhibit 99.1 Consent to be Named as a Director Pulmatrix, Inc. is filing a Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and supplements thereto as a future member of the b…
Read attachment ↗ex99-2.htm · S-4 · 2026-07-09
EX-99.2 14 ex99-2.htm EX-99.2 Exhibit 99.2 Consent to be Named as a Director Pulmatrix, Inc. is filing a Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and supplements thereto as a future member of the b…
Read attachment ↗ex99-1.htm · 8-K · 2026-05-15
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Pulmatrix Announces First Quarter 2026 Financial Results Announced merger agreement with Eos SENOLYTIX in March Closed private placement of preferred stock Framingham, Mass., May 15, 2026 - Pulmatrix, Inc. (“Pulmatrix” or the “Company”) (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical ne…
Read attachment ↗ex99-1.htm · 8-K · 2026-04-21
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger Series B Preferred Stock investment made in Pulmatrix with a conversion price of $2.20 is a part of the ongoing merger process Framingham, Mass., April 21, 2026 - Pulmatrix, Inc. (“Pulmatrix” or the “Company”) (Nasdaq: PULM), today announced the closing of its previously announced private placement of Series B Convertible Preferred Stock (“Series B Preferred Stock…
Read attachment ↗